Finch Therapeutics Group Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Matt Blischak
Chief executive officer
US$775.7k
Total compensation
| CEO salary percentage | 32.5% |
| CEO tenure | 1.8yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration
Sep 01Finch to get back rights to IBD product candidates after Takeda ends collaboration
Aug 25Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M
Aug 11Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Mar 15
Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Dec 15We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully
Aug 28Finch Therapeutics: Gut Instinct Says Buy
Jun 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$14m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$776k | US$252k | -US$75m |
Compensation vs Market: Matt's total compensation ($USD775.65K) is about average for companies of similar size in the US market ($USD640.24K).
Compensation vs Earnings: Insufficient data to compare Matt's compensation with company performance.
CEO
Matt Blischak (61 yo)
1.8yrs
Tenure
US$775,651
Compensation
Mr. Matthew P. Blischak, also known as Matt, JD, serves as Chief Executive Officer of Finch Therapeutics Group, Inc. since May 16, 2023 and serves as its President & Secretary since May 2023. He has intell...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 8yrs | US$2.29k | 2.63% $ 475.4k | |
| Independent Director | 4.4yrs | US$2.29k | 26.24% $ 4.7m | |
| Independent Chair | 7.4yrs | US$2.29k | 0% $ 0 | |
| Independent Director | 5.4yrs | US$2.29k | 1.32% $ 238.6k |
6.4yrs
Average Tenure
58yo
Average Age
Experienced Board: FNCH's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/03 23:02 |
| End of Day Share Price | 2025/02/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Finch Therapeutics Group, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Maneka Mirchandaney | Evercore ISI |
| Vernon Bernardino | H.C. Wainwright & Co. |